Catalyst Biosciences Inc., of South San Francisco, said it closed an underwritten public offering of approximately 5.3 million common shares at $6.50 apiece, which included the full exercise of the 30-day option by underwriters to purchase up to 692,307 additional shares, for gross proceeds of approximately $34.5 million. Net proceeds will be used, in part, for clinical and manufacturing activities for the factor VIIa agonist marzeptacog alfa and factor IX agonist dalcinonacog alfa, both aimed at the treatment of bleeding disorders, along with R&D activities and other corporate needs. Raymond James & Associates Inc. was sole book-running manager, with Jonestrading Institutional Services LLC, Chardan and Lifesci Capital LLC as co-managers for the offering.
Genprex Inc., of Austin, Texas, said it priced an at-the-market registered direct offering of 5 million common shares to institutional investors at $3.50 apiece for gross proceeds of approximately $17.5 million. Net proceeds will be used to advance the company’s lead programs in non-small-cell lung cancer and for other corporate purposes. A.G.P./Alliance Global Partners is lead placement agent and Joseph Gunnar & Co. LLC is co-placement agent for the offering, expected to close by Feb. 21. Genprex shares (NASDAQ:GNPX) closed Feb. 19 at $3.90 for a loss of $1.
Mereo Biopharma Group plc, of London, said a U.S.-based institutional health care investor agreed to invest $3 million through the purchase of approximately 12.3 million ordinary shares (equivalent to approximately 2.5 million American depository shares) at 18.8 pence (US24 cents) apiece, representing a 20% discount over Mereo’s Feb. 18 closing price of 23.5 pence on London’s AIM, where the stock trades as MPH. The company did not disclose specific use of proceeds from the private offering.
Revolution Medicines Inc., of Redwood City, Calif., said it closed its IPO of 16.1 million common shares, including full exercise by the underwriters of their option to purchase 2.1 additional shares, at $17 apiece for gross proceeds of approximately $273.7 million. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities were joint bookrunners. On Feb. 19, the company’s shares (NASDAQ:RVMD) gained $1.33 to close at $30.38.